| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 9, 2022Oral Presentation: Initial Data from ASCEND Study Highlights STS101’s Long-Term Safety and Tolerability
South San Francisco, CA, June 9, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel...
-
Jun 7, 2022Thursday, June 16th @ 10:30 a.m. ET
South San Francisco, CA, June 07, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
May 11, 2022
South San Francisco, CA, May 11, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel...
-
May 10, 2022- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 -
South San Francisco, CA, May 10, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel...
-
Mar 15, 2022- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 -
South San Francisco, CA, March 15, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Mar 3, 2022
South San Francisco, CA, March 3, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Feb 8, 2022
South San Francisco, CA, February 8, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Nov 9, 2021- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 -
South San Francisco, CA, November 9, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Oct 28, 2021
South San Francisco, CA, October 28, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Oct 12, 2021
South San Francisco, CA, October 12, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Sep 28, 2021
South San Francisco, CA, September 28, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Sep 8, 2021
South San Francisco, CA, September 8, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Aug 10, 2021Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022-
South San Francisco, CA, August 10, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Jul 28, 2021
South San Francisco, CA, July 28, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine...
-
Jun 22, 2021
June 22, 2021 South San Francisco, CA, June 22, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal...
-
Jun 16, 2021- All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile -
South San Francisco, CA, June 16, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
May 11, 2021-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022-
South San Francisco, CA, May 11, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101, a novel therapeutic product candidate for the...
-
Mar 25, 2021- Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022
South San Francisco, CA, March 25, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101, a novel therapeutic product candidate for...
-
Mar 10, 2021
March 10, 2021 South San Francisco, CA, March 10, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present a...
-
Mar 1, 2021
South San Francisco, CA, March 1, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that it has agreed to sell 14,084,507 shares of...
-
Mar 1, 2021-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-
South San Francisco, CA, March 1, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced an update to the development plan for STS101...
-
Nov 24, 2020
South San Francisco, CA, November 24, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the...
-
Nov 10, 2020Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021
South San Francisco, CA, November 10, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company focused on developing STS101 (a dihydroergotamine (DHE)...
-
Nov 2, 2020- Credit Suisse - 29th Annual Healthcare Conference - November 9th -12th
South San Francisco, CA, November 2, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the...
-
Sep 10, 2020- Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration
South San Francisco, CA, September 10, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced topline results from its Phase 3 EMERGE...